SynthesisEuropean journal of clinical pharmacology2025

Cost-effectiveness of rivaroxaban plus aspirin versus aspirin alone in patients with stable coronary artery disease or peripheral artery disease: a systematic review.

Jalal Arabloo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.